Clinical Trials

Accrual Status
Limit to SWOG Trials

1028 Results

    View
    Closed
    Phase
    Accrual
    100%
    SWOG Clinical Trial Number
    S1416

    Phase II Randomized Placebo-Controlled Trial of Cisplatin with or without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer (TNBC) and/or BRCA Mutation-Associated Breast Cancer, with or without Brain Metastases
    Status Notes
    S1416 will permanently close to accrual on 6/15/19.
    Research Committee(s)
    Breast Cancer
    Activated
    07-07-2016
    Closed
    06-15-2019
    Closed
    Phase
    Accrual
    100%
    SWOG Clinical Trial Number
    S1417CD

    Implementation of a Prospective Financial Impact Assessment Tool in Patients with Metastatic Colorectal Cancer
    Research Committee(s)
    Cancer Care Delivery
    Gastrointestinal Cancer
    Activated
    04-15-2016
    Closed
    02-01-2019
    ClinicalTrials.gov Registry Number
    NCT02728804
    Closed
    Phase
    Accrual
    100%
    SWOG Clinical Trial Number
    S1500

    A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511])in Metastatic Papillary Renal Carcinoma (PAPMET)
    Status Notes
    Arms 3 and 4 of the study referenced above are permanently closed to accrual effective 12/5/18. Arms 1 and 2 are active to accrual effective 1/22/19.

    Research Committee(s)
    Genitourinary Cancer
    Activated
    04-05-2016
    ClinicalTrials.gov Registry Number
    NCT02761057
    Closed
    Phase
    Accrual
    79%
    SWOG Clinical Trial Number
    S1400I

    A BIOMARKER-DRIVEN MASTER PROTOCOL FOR PREVIOUSLY TREATED SQUAMOUS CELL LUNG CANCER - A PHASE III RANDOMIZED STUDY OF NIVOLUMAB PLUS IPILIMUMAB VERSUS NIVOLUMAB FOR PREVIOUSLY TREATED PATIENTS WITH STAGE IV SQUAMOUS CELL LUNG CANCER AND NO MATCHING BIOMARKER
    Status Notes
    Effective 3:00 p.m. Pacific Time on April 23, 2018, S1400I will be permanently closed to accrual.

    This is a potential FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
    Research Committee(s)
    Lung Cancer
    Activated
    12-18-2015
    Closed
    04-23-2018
    Closed
    Phase
    Accrual
    98%
    SWOG Clinical Trial Number
    S1404

    A Phase III Randomized Trial of Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High-Risk Resected Melanoma -
    Status Notes
    Step 2 (randomization) of the above-referenced study will be permanently closed to accrual effective November 2, 2017 at 11:59 p.m. Pacific Time.

    Closure to Step 1 (prestudy screening) was effective August 15th.



    NOTE: This is a potential FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
    Research Committee(s)
    Melanoma
    Symptom Control and Quality of Life
    Activated
    10-15-2015
    ClinicalTrials.gov Registry Number
    NCT02506153
    Closed
    Phase
    Accrual
    98%
    SWOG Clinical Trial Number
    S1505

    A Randomized Phase II Study of Perioperative mFOLFIRINOX versus Gemcitabine/nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma
    Status Notes
    S1505 is now closed to accrual as of 04/20/2018.
    Research Committee(s)
    Gastrointestinal Cancer
    Activated
    10-12-2015
    ClinicalTrials.gov Registry Number
    NCT02562716
    Closed
    Phase
    Accrual
    29%
    SWOG Clinical Trial Number
    S1403

    A Randomized Phase II Trial of Afatinib Plus Cetuximab Versus Afatinib Alone In Treatment-Naïve Patients With Advanced, EGFR Mutation Positive Non-Small Lung Cancer (NSCLC)
    Status Notes
    This study permanently closed to accrual effective April 23, 2018.
    Research Committee(s)
    Lung Cancer
    Activated
    03-25-2015
    Closed
    04-23-2018
    Closed
    Phase
    Accrual
    100%
    SWOG Clinical Trial Number
    S1316

    Prospective Comparative Effectiveness Trial for Malignant Bowel Obstruction
    Status Notes
    Re-Activation - Effective 6/1/18
    Research Committee(s)
    Cancer Survivorship
    Gastrointestinal Cancer
    Activated
    03-09-2015
    ClinicalTrials.gov Registry Number
    NCT02270450
    Closed
    Phase
    Accrual
    98%
    SWOG Clinical Trial Number
    S1318

    A Phase II Study of Blinatumomab (NSC-765986) and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients >/= 65 Years of Age with Newly Diagnosed Philadelphia Chromosome Negative (Ph-) Acute Lymphocytic Leukemia (ALL) and of Dasatinib (NSC-732517), Prednisone and Blinatumomab for Patients >/= 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL (Newly Diagnosed or Relapsed/Refractory) with Known or Presumed Activating Dastainib-Sensitive Mutations or Kinase Fusions (DSMKF)
    Research Committee(s)
    Leukemia
    Activated
    01-12-2015
    Closed
    09-29-2021
    ClinicalTrials.gov Registry Number
    02143414
    Closed
    Phase
    Accrual
    100%
    SWOG Clinical Trial Number
    S1406

    Randomized Phase II Study of Irinotecan and Cetuximab with or without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer
    Research Committee(s)
    Gastrointestinal Cancer
    Activated
    11-13-2014
    Closed
    04-01-2016
    ClinicalTrials.gov Registry Number
    NCT02164916
    Closed
    Phase
    Accrual
    1%
    SWOG Clinical Trial Number
    S1300

    A Randomized, Phase II Trial of Crizotinib Plus Pemetrexed Versus Pemetrexed Monotherapy in ALK-Positive Non-Squamous NSCLC Patients Who Have Progressed Systemically After Previous Clinical Benefit from Crizotinib Monotherapy
    Status Notes
    This study will permanently close to accrual on September 1, 2016 at 11:59 p.m. Pacific.
    Research Committee(s)
    Lung Cancer
    Activated
    08-01-2014
    Closed
    09-01-2016
    ClinicalTrials.gov Registry Number
    NCT #02134912
    Closed
    Phase
    Accrual
    100%
    SWOG Clinical Trial Number
    S1320

    A Randomized Phase II Trial of Intermittent Versus Continuous Dosing Of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E/K Mutant Melanoma
    Status Notes
    Effective 7/15/2019, Step 2 registration (randomization) is permanently closed to accrual.

    <b>Effective 4/19/19, Step 1 (lead‐in continuous dosing) will be permanently closed to accrual effective April 19, 2019 at 11:59 p.m. Pacific Time.

    All patients who have consented must be registered to Step 1 (lead‐in continuous dosing) prior to 11:59 p.m. PT on April 19, 2019 in order to be eligible to participate. This closure does not apply to Step 2 randomization</b>
    Research Committee(s)
    Melanoma
    Activated
    07-22-2014
    Closed
    07-15-2019
    ClinicalTrials.gov Registry Number
    NCT02199730
    Closed
    Phase
    Accrual
    100%
    SWOG Clinical Trial Number
    S1314

    A Randomized Phase II Study of CO-eXpression ExtrapolatioN (COXEN)-Directed Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer
    Research Committee(s)
    Genitourinary Cancer
    Activated
    07-09-2014
    Closed
    12-01-2017
    ClinicalTrials.gov Registry Number
    NCT02177695
    Closed
    Phase
    SWOG Clinical Trial Number
    S1400

    A BIOMARKER-DRIVEN MASTER PROTOCOL FOR PREVIOUSLY TREATED SQUAMOUS CELL LUNG CANCER (LUNG-MAP)
    Status Notes
    The S1400 screening protocol will close to accrual and be replaced by the new Lung-MAP screening protocol, called LUNGMAP, which will open to accrual January 28, 2019, effective 2:00 pm PST.

    This is a potential FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
    Research Committee(s)
    LungMAP
    Head and Neck Cancer
    Lung Cancer
    Activated
    06-15-2014
    ClinicalTrials.gov Registry Number
    NCT02154490
    Closed
    Phase
    Accrual
    83%
    SWOG Clinical Trial Number
    S1400A

    A BIOMARKER-DRIVEN MASTER PROTOCOL FOR PREVIOUSLY TREATED SQUAMOUS CELL LUNG CANCER (LUNG-MAP) - A PHASE II STUDY OF MEDI4736 FOR PREVIOUSLY TREATED PATIENTS WITH STAGE IV SQUAMOUS CELL LUNG CANCER AND NO MATCHING BIOMARKERS (LUNG-MAP SUB-STUDY)
    Status Notes
    This sub-study will be permanently closed to accrual on 12/18/15 at 2:00 p.m. Pacific
    Research Committee(s)
    Lung Cancer
    Activated
    06-15-2014
    Closed
    11-18-2015
    Closed
    Phase
    Accrual
    57%
    SWOG Clinical Trial Number
    S1400B

    A BIOMARKER-DRIVEN MASTER PROTOCOL FOR PREVIOUSLY TREATED SQUAMOUS CELL LUNG CANCER - A PHASE II STUDY OF GDC-0032 (TASELISIB) FOR PREVIOUSLY TREATED PI3K POSITIVE PATIENTS WITH STAGE IV SQUAMOUS CELL LUNG CANCER
    Status Notes
    Effective 11:59 p.m. Pacific Time on December 12, 2016, S1400B will be permanently closed to accrual.
    Research Committee(s)
    Lung Cancer
    Activated
    06-15-2014
    Closed
    12-12-2016
    Closed
    Phase
    Accrual
    81%
    SWOG Clinical Trial Number
    S1400D

    A BIOMARKER DRIVEN MASTER PROTOCOL FOR PREVIOUSLY TREATED SQUAMOUS CELL LUNG CANCER - A PHASE II STUDY OF AZD4547 FOR PREVIOUSLY TREATED FGFR-POSITIVE PATIENTS WITH STAGE IV SQUAMOUS CELL LUNG CANCER
    Status Notes
    Effective 11:59 p.m. Pacific Time on October 31, 2016, the following sub-study will be permanently closed to accrual.
    Research Committee(s)
    Lung Cancer
    Activated
    06-15-2014
    Closed
    10-31-2016
    Closed
    Phase
    Accrual
    91%
    SWOG Clinical Trial Number
    S1400C

    A BIOMARKER-DRIVEN MASTER PROTOCOL FOR PREVIOUSLY TREATED SQUAMOUS CELL LUNG CANCER - A PHASE II STUDYOF PALBOCICLIB FOR PREVIOUSLY TREATED CELL CYCLE GENE ALTERATION POSITIVE PATIENTS WITH STAGE IV SQUAMOUS CELL LUNG CANCER
    Status Notes
    Effective 11:59 p.m. Pacific Time on September 1, 2016, S1400C will be permanently closed to accrual.
    Research Committee(s)
    Lung Cancer
    Activated
    06-15-2014
    Closed
    Phase
    Accrual
    3%
    SWOG Clinical Trial Number
    S1400E

    Phase II/III Randomized Study of Rilotumumab plus Erlotinib versus Erlotinib as Second Line Therapy For Biomarker Selected Patients With Squamous Cell Lung Cancer
    Status Notes
    This sub-study will be permanently closed to accrual on 11/24/2014 at 2:00 p.m. Pacific
    Research Committee(s)
    Lung Cancer
    Activated
    06-15-2014
    Closed
    11-25-2014
    Closed
    Phase
    Accrual
    4%
    SWOG Clinical Trial Number
    S1222

    Fulvestrant Alone Versus Fulvestrant and Everolimus Versus Fulvestrant, Everolimus and Anastrozole: A Phase III Randomized Placebo-Controlled Trial In Postmenopausal Patients With Hormone-Receptor Positive Stage IV Breast Cancer.
    Status Notes
    NOTE: This study is permanently closed to accrual effective 10/15/2015.
    Research Committee(s)
    Breast Cancer
    Activated
    05-09-2014
    Closed
    10-15-2015
    ClinicalTrials.gov Registry Number
    NCT02137837